key: cord-0831376-drocp6f3
authors: To, Kelvin Kai-Wang; Hung, Ivan Fan-Ngai; Ip, Jonathan Daniel; Chu, Allen Wing-Ho; Chan, Wan-Mui; Tam, Anthony Raymond; Fong, Carol Ho-Yan; Yuan, Shuofeng; Tsoi, Hoi-Wah; Ng, Anthony Chin-Ki; Lee, Larry Lap-Yip; Wan, Polk; Tso, Eugene; To, Wing-Kin; Tsang, Dominic; Chan, Kwok-Hung; Huang, Jian-Dong; Kok, Kin-Hang; Cheng, Vincent Chi-Chung; Yuen, Kwok-Yung
title: COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing
date: 2020-08-25
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa1275
sha: 85b7061408fba3a765b4896ebb3aea6b2c1d0995
doc_id: 831376
cord_uid: drocp6f3

BACKGROUND: Waning immunity occurs in patients who have recovered from COVID-19. However, it remains unclear whether true re-infection occurs. METHODS: Whole genome sequencing was performed directly on respiratory specimens collected during two episodes of COVID-19 in a patient. Comparative genome analysis was conducted to differentiate re-infection from persistent viral shedding. Laboratory results, including RT-PCR Ct values and serum SARS-CoV-2 IgG, were analyzed. RESULTS: The second episode of asymptomatic infection occurred 142 days after the first symptomatic episode in an apparently immunocompetent patient. During the second episode, there was serological evidence of elevated C-reactive protein and SARS-CoV-2 IgG seroconversion. Viral genomes from first and second episodes belong to different clades/lineages. Compared to viral genomes in GISAID, the first virus genome has a stop codon at position 64 of orf8 leading to a truncation of 58 amino acids, and was phylogenetically closely related to strains collected in March/April 2020, while the second virus genome was closely related to strains collected in July/August 2020. Another 23 nucleotide and 13 amino acid differences located in 9 different proteins, including positions of B and T cell epitopes, were found between viruses from the first and second episodes. CONCLUSIONS: Epidemiological, clinical, serological and genomic analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Our results suggest SARS-CoV-2 may continue to circulate among the human populations despite herd immunity due to natural infection or vaccination. Further studies of patients with re-infection will shed light on protective correlates important for vaccine design.

The second episode of asymptomatic infection occurred 142 days after the first symptomatic episode in an apparently immunocompetent patient. During the second episode, there was serological evidence of elevated C-reactive protein and SARS-CoV-2 IgG seroconversion. Viral genomes from first and second episodes belong to different clades/lineages. Compared to viral genomes in GISAID, the first virus genome has a stop codon at position 64 of orf8 leading to a truncation of 58 amino acids, and was phylogenetically closely related to strains collected in March/April 2020, while the second virus genome was closely related to strains collected in July/August 2020. Another 23 nucleotide and 13 amino acid differences located in 9 different proteins, including positions of B and T cell epitopes, were found between viruses from the first and second episodes.

Epidemiological, clinical, serological and genomic analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Our results suggest SARS-CoV-2 may continue to circulate among the human populations despite herd immunity due to natural infection or vaccination. Further studies of patients with re-infection will shed INTRODUCTION COVID-19 pandemic has affected over 23 million patients with more than 0.8 million deaths in over 200 countries. The pandemic has severely disrupted the healthcare system and halted socioeconomic activities. Household transmission has led to familial clusters [1, 2] .

The high transmissibility of the etiological agent SARS coronavirus 2 (SARS-CoV-2) by airborne, droplet and contact routes has led to large outbreaks in eateries, bars, cruise ships, workplaces, and healthcare institutions [3] . With the exception of few regions, COVID-19 continues to circulate worldwide despite stringent control measures. Moreover, many areas experienced resurgence of cases after relaxation of social distancing policies [4] .

One of the key questions for COVID-19 is whether true re-infection occurs. Although neutralizing antibody develops rapidly after infection [5, 6] , recent studies showed that antibody titers start to decline as early as 1-2 months after the acute infection [7, 8] . Due to prolonged viral shedding at low levels near the detection limit of RT-PCR assays [5] , patients tested negative and discharged from hospitals are often having recurrence of positive results [9] . A case report suggested that re-infection can occur, but viral genome analysis was not performed [10] . These reported cases have raised the controversy between persistent virus shedding and re-infection.

We have encountered a patient with a second episode of infection which occurred 4.5 months after the first episode. Here, we differentiated re-infection from prolonged viral shedding using whole genome analysis to discriminate re-infection from prolonged viral shedding, which was also supported by epidemiological, clinical and serological data.

SARS-CoV-2 RT-PCR was performed using the LightMix® E-gene kit as we described previously [11] . Immunoglobulin G (IgG) against SARS-CoV-2 nucleoprotein was performed using Abbott SARS-CoV-2 IgG assay or microsphere-based antibody as we described previously [12] .

RNA was extracted from posterior oropharyngeal saliva using Qiagen Viral RNA Mini Kit as we described previously [4] . Reverse transcription was performed using SuperScript IV reverse transcriptase (ThermoFisher Scientific, Waltham, MA, USA). The cDNA was then used for tiling PCR according to Nanopore protocol -PCR tiling of COVID-19 (Version: PTC_9096_v109_revF_06Feb2020) with modifications [4] . Nanopore sequencing library preparation was prepared according to the PCR tiling of COVID-19 virus protocol for end preparation and native barcode ligation (EXP-NBD196, Oxford Nanopore Technologies). Barcoded and pooled libraries were then ligated to sequencing adapter and sequenced with the Oxford Nanopore MinION device using R9.4.1 flow cell.

Bioinformatics analysis of nanopore sequencing data was performed using the ARTIC-nCoV network workflow [13] with minor modifications for converting raw data into the consensus sequences using the Medaka pipeline. The modifications include increasing the QC passing score from 7 to 10, reducing the minimum length at the guppyplex step to 350 to allow potential deletions to be detected, and increasing the "-normalise" value to 999999 to incorporate all the sequenced reads.

Multiple alignment was performed using MAFFT [14] . Maximum-likelihood whole genome phylogenetic tree was constructed using IQ-TREE2 [15] , with substitution model TIM2+F as the best predicted model by BIC. The option -czb was used to mask unrelated substructure of the tree with near zero branch length. The ultrafast bootstrap option was used with 1000 replicates. We described the clade information using GISAID [16] , Nextstrain [17] and Pangolin [18] nomenclatures. Nucleotide position was numbered according to the reference genome Wuhan-Hu-1 (GenBank accession number MN908947.3).

To identify strains that are most closely related to those of the patient, strains in the GISAID database deposited as of August 20, 2020 were analyzed (Supplementary Table S1 ).

The file downloaded from GISAID (msa_0820) has excluded duplicate and low-quality sequences with >5% NNNNs. The following criteria were used for strain inclusion for the phylogenetic analysis. We blast-searched whole viral genome against the GISAID database using the two strains from the patient, and included the 10 top hits for each blast. BLAST+ toolkit was used for the blast searches [19] (Supplementary Table S1 ). In addition to the 20 chosen strains from the BLAST results, we have also included previously from Hong Kong in our previous publication [4] , and 5 most recent strains from UK and Spain and 3 other early reported strains were included in the tree for referencing.

The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster UW 13-265. The patient has also provided written informed consent for publication. 8 The patient was a 33-year old male residing in Hong Kong. He enjoyed a good past health. During the first episode, he presented with cough and sputum, sore throat, fever and headache for 3 days. Figure 1 ). On admission, C-reactive protein (CRP) level was slightly elevated at 8.6 mg/L, but declined during hospitalization ( Figure 1 ). There was also hypokalemia, but other blood test results were normal (Table 1) . Serial chest radiographs did not reveal any abnormalities.

No antiviral treatment was given to the patient. Serial real-time RT-PCR Ct values in the posterior oropharyngeal saliva gradually declined during hospitalization, indicating a decrease in viral load ( Figure 1 ).

The serum specimens collected 10 days after symptom onset for the first episode and 1 day after hospitalization for the second episode tested negative for IgG against SARS-CoV-2 nucleoprotein. Serial serum specimens collected during the second episode were also tested 9 for SARS-CoV-2 IgG using Abbott assay, with the serum specimen collected from day 1 to 3 after hospitalization tested negative but a subsequent serum specimen collected on day 5 after hospitalization was tested positive.

Whole genome sequencing was performed from posterior oropharyngeal saliva specimens collected during the first episode in March and from the second episode in August. Table S2 ). 10 We have performed a blast search for the first and second genome. The first viral genome is most closely related to strains from the USA or England collected in March and April 2020. The second viral genome is most closely related to strains from Switzerland and England collected in July and August 2020. The second genome contains the mutation nsp6 L142F, which is rarely found (0.009% [7/76828] genomes deposited into GISAID as of August 20, 2020).

We report the first case of re-infection of COVID-19. Several lines of evidence supported that the second episode is related to re-infection instead of prolonged viral shedding. First, whole genome analysis showed that the SARS-CoV-2 strains from the first and second episode belong to different clades/lineages with 24 nucleotide differences, suggesting that the virus strain detected in the second episode is completely different from the strain found in the first episode. Second, the patient had elevated CRP, relatively high viral load with gradual decline, and seroconversion of SARS-CoV-2 IgG during the second episode, suggesting that this is a genuine episode of acute infection. Third, there was an interval of 142 days between the first and second episode. Previous studies have shown that viral RNA is undetectable one month after symptom onset for most patients [5, 20, 21] . Prolonged viral shedding for over one month has been reported but rare [21, 22] . In one report, a pregnant woman had virus detected for 104 days after her initial positive test [23] .

Fourth, the patient has recently traveled to Europe, where resurgence of COVID-19 cases has occurred since late July, 2020. The viral genome obtained during the second episode is phylogenetically closely related to strains collected from Europe in July and August.

The confirmation of re-infection has several important implications. First, it is unlikely that herd immunity can eliminate SARS-CoV-2, although it is possible that 11 subsequent infections may be milder than the first infection as for this patient. COVID-19

will likely continue to circulate in the human population as in the case of other human coronaviruses. Re-infection is common for "seasonal" coronaviruses 229E, OC43, NL63 and HKU1 [24] . In some instances, re-infection occurs despite a static level of specific antibodies.

Second, vaccines may not be able to provide lifelong protection against COVID-19.

Furthermore, vaccine studies should also include patients who recovered from COVID-19.

Despite having an acute infection as evidenced by an elevated CRP and serocoversion, the patient was asymptomatic during the second episode. A previous study of re-infection in rhesus macaque also showed a milder illness during the re-infection [25] . This is likely related to the priming of the patient's adaptive immunity during the first infection.

During SARS-CoV-2 infection, neutralizing antibody develops in most patients. In our patient, although anti-SARS-CoV-2 antibody was not detected initially during the second episode, the residual low titer of antibody may have partially controlled the virus. Since neutralizing antibodies target the spike protein [26] , variations in the spike protein may render the virus less susceptible to neutralizing antibodies which were induced during the first infection. Several mutations in the spike protein receptor binding domain and N-terminal domain have been shown to confer reduced susceptibility to neutralizing antibodies [27] . For our patient, there are four amino acid residues that differ in the spike protein between the first and second infection, including L18F, A222V, D614G and Q780E. Amino acid residue 222 and 614 are located within the B cell immunodominant epitopes which we have previously identified [28] . A222V and D614G may affect the structure of these epitopes (Supplementary Figure S1 ). D614G, located at the subdomain 2 of the spike protein, and is now found in most SARS-CoV-2 strains. Studies using pseudovirus suggest that D614G enhances the replication of SARS-CoV-2 [29] . A recent study using pseudovirus showed that 7% of convalescent sera from recovered COVID-19 patients had reduced serum neutralizing activity against 614G than 614D [30] . Further serological studies are required to determine whether these amino acid differences in the spike protein of the SARS-CoV-2 strains between the first and second infection is responsible for the re-infection.

T cell immunity may also play a role in ameliorating the severity during re-infection.

Studies with coronaviruses before the COVID-19 pandemic showed that coronaviruses can induce long-lasting T cell immunity [31] . T cell immunity mainly targets the spike protein, although CD4 or CD8+ T cell response against other viral proteins can be found [31] [32] [33] [34] .

Grifoni et al showed that both CD4+ T cell mainly targets the structural proteins (spike, membrane and nucleoprotein) [33] . CD4+ T cells also targets the nsp3, nsp4 and ORF8, while the CD8+ T cells target the nsp6, ORF3a and ORF8. T cell immunity can be detected in recovered COVID-19 patients several months after the initial infection [35] . One of the amino acid change was located in the Spike protein amino acid residue 222 which is also a potential site eliciting CD4+ T cell responses [36] .

IgG against SARS-CoV-2 was undetectable in the blood collected shortly after the diagnosis during the second episode. The low antibody level may be related to his mild illness during the first episode. We and others have shown that patients with milder disease had lower antibody titers than those with severe disease [6, 7] .

The lack of antibody response after COVID-19 can have implications on both the susceptibility to re-infection and the severity of infection. Although our patient is asymptomatic during the second infection, it is possible that re-infection may result in more severe infection. Our previous study on SARS-CoV showed that antibodies against the spike protein can be associated with more severe acute lung injury [37] . However, during the second episode of infection in our patient, IgG against SARS-CoV-2 was not detected until 5 days after hospitalization. One possibility is that he did not mount an antibody response after the first infection, but this cannot be ascertained as we only had the archived serum collected 13 10 days after the onset of symptoms for the first episode. Previous studies have shown that antibody response was not detectable in some patients until 2-3 weeks after onset of symptoms. Another possibility is the he indeed mount an antibody response after the first infection, but the antibody titer deceases below the detection limit of the assays. This waning of antibody has been well described. In one study, 33% of recovered COVID-19 patients were negative for neutralizing antibodies during the convalescent phase (average 39 days after symptom onset) [8] . Another study showed that 40% of asymptomatic individuals are seronegative within 8 weeks after the onset of symptoms [7] . Besides the lack of protection against re-infection, another implication of rapid decline in antibody titers is that seroprevalence studies may underestimate the true prevalence of infection.

There are several limitations in this study. First, we only have one serum specimen collected for the first episode. Since patients may not mount antibody response within 10 days, the negative antibody test does not exclude the possibility that the patient indeed developed antibody response during the early convalescent phase for the first episode.

Second, the virus culture using upper respiratory tract specimens from both episodes are still ongoing, and therefore the neutralizing antibody titer against the virus from the first and second episode cannot be compared.

This case illustrates that re-infection can occur even just after a few months of recovery from the first infection. Our findings suggest that SARS-CoV-2 may persist in humans as is the case for other common-cold associated human coronaviruses, even if patients have acquired immunity via natural infection or via vaccination. In rhesus macaques that have recovered from SARS-CoV-2 infection and re-challenged with the same virus, the peak viral load during re-challenge was >5 log 10 lower in the BAL but only ~2 log10 lower in the nasal swab when compared with those during the first challenge [25] . Similarly, in vaccine studies, viral RNA could still be detected in the upper respiratory tract for vaccinated 14 animals [38] . Further studies on re-infection, which will be vital for the research and development of more effective vaccine, are warranted. In summary, reinfection is possible 4.5 months after a first episode of symptomatic infection. Vaccination should also be considered for those with one episode of infection. Even those with previous COVID-19 infection should comply with epidemiological control measures such as universal masking and social distancing. 

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Seroprevalence of SARS-CoV-2 in Hong Kong Special Administrative Region and our returnees evacuated from Hubei province of China: a multi-cohort study

shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series

Unique SARS-CoV-2 clusters causing a large COVID-19 outbreak in Hong Kong

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

High neutralizing antibody titer in intensive care unit patients with COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation

A case report of possible novel coronavirus 2019 reinfection

Evaluation of the commercially available LightMix(R) Modular E-gene kit using clinical and proficiency testing specimens for SARS-CoV-2 detection

Improved detection of antibody against SARS-CoV-2 by microsphere-based antibody assay

Artic Network-nCoV 2019 sequencing protocol

MAFFT multiple sequence alignment software version 7: improvements in performance and usability

IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era

Clade and lineage nomenclature aids in genomic epidemiology studies of active hCoV-19 viruses

clarifications/clade-and-lineage-nomenclature-aids-in-genomic-epidemiology-of-active-hcov-19-viruses

Year-letter Genetic Clade Naming for SARS-CoV-2 on Nextstain

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

BLAST+: architecture and applications

Associations of viral ribonucleic acid (RNA) shedding patterns with clinical illness and immune responses in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Decreased B Cells on Admission Associated With Prolonged Viral RNA Shedding From the Respiratory Tract in Coronavirus Disease 2019: A Case-Control Study

Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion

Coronavirus protective immunity is short-lasting

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Mining of epitopes on spike protein of SARS-CoV-2 from COVID-19 patients

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

The D614G mutation of SARS-CoV-2 spike protein enhances viral infectivity and decreases neutralization sensitivity to individual convalescent sera

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with

Disease and Unexposed Individuals

Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses

Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

We gratefully acknowledge the originating and submitting laboratories who 

All authors declare no conflict of interest. 16